NanoViricides, Inc. (NYSE American: NNVC) highlighted that its antiviral drug candidate NV-387 may address the growing global measles outbreak, citing recent case surges including more than 18,000 suspected infections in Bangladesh and rising cases in the United States. The company stated that NV-387 has demonstrated safety in Phase I clinical trials and efficacy in animal models, positioning it as a potential therapeutic complement to vaccination by reducing transmission and treating infected patients, particularly among vulnerable populations.
The announcement comes as measles cases continue to rise worldwide, underscoring the need for effective treatments. NV-387 is a broad-spectrum antiviral drug that has shown effectiveness in animal models for not only measles but also monkeypox, smallpox, and various respiratory viral infections. The company plans to pursue orphan and rare pediatric disease designations with the FDA, which could accelerate development and provide incentives for targeting measles.
According to the press release, available at https://ibn.fm/YQsvK, NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is now focused on advancing NV-387 into Phase II human clinical trials. NanoViricides, a clinical stage company, creates special purpose nanomaterials for antiviral therapy. Their lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.
The potential of NV-387 to address measles is significant given the current global outbreak. Measles is highly contagious, and while vaccination is effective, breakthrough infections can occur, particularly in immunocompromised individuals. An effective antiviral could help reduce transmission and severity of the disease. The company's plans to seek FDA designations could expedite the drug's path to market.
For more information about NanoViricides and its pipeline, visit their website at http://www.nanoviricides.com and follow updates in the company's newsroom at https://ibn.fm/NNVC.
